Alivus Life Sciences Limited — Investor Meet, 08-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Alivus Life Sciences Q1 FY26: Revenue at INR 602 Cr (+2.2% YoY), EBITDA at INR 181 Cr (+9.9% YoY) with 30.1% margin. Non-GPL business showed strong 14.5% YoY growth, despite a 22% decline in GPL business. Management expects stronger H2, maintaining mid-teens volume growth and high single-digit revenue for FY26. CDMO projects, including a 5th, are set for H2 ramp-up, targeting 12-15% of revenue in 4-5 years. Company remains net debt-free with INR 660 Cr cash. Confident in pipeline and exploring inorganic growth opportunities. #AlivusLife #Earnings